That’s a bingo. We have no good idea, IMHO. The study likely provided an unlikely low estimate, in the low single digits. You probably sense my frustration as I wrote at the end of the piece:

How typical is Paxlovid’s rebound? Are we as infectious during the rebound COVID as the original? What is the length of the rebound period? Is the rebound associated with long COVID? And do we have any evidence that a five-day course of Paxlovid is too short?

Will keep you posted as the information comes in over the next several months. For high-risk individuals, I think I lean yes to paxlovid, but as I am not in that category, I would not use it myself unless I had a more than typical severity of disease.

Thanks for reading the piece and for your observations.

Michael